Absci reports business updates and first quarter 2024 financial and operating results

Initiated ind-enabling studies for abs-101 in february continuing to advance abs-201 and abs-301 through preclinical studies vancouver, wash. and new york, may 14, 2024 (globe newswire) -- absci corporation (nasdaq: absi), a data-first generative ai drug creation company, today reported financial and operating results for the quarter ended march 31, 2024.
ABSI Ratings Summary
ABSI Quant Ranking